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FERRUA ET AL 2239Background: CD40 ligand (CD40L) deficiency, an X-linked
primary immunodeficiency, causes recurrent sinopulmonary,
Pneumocystis and Cryptosporidium species infections. Long-term
survival with supportive therapy is poor. Currently, the only
curative treatment is hematopoietic stem cell transplantation
(HSCT).
Objective: We performed an international collaborative study
to improve patients’ management, aiming to individualize risk
factors and determine optimal HSCT characteristics.
Methods: We retrospectively collected data on 130 patients who
underwent HSCT for CD40L deficiency between 1993-2015. We
analyzed outcome and variables’ relevance with respect to
survival and cure.
Results: Overall survival (OS), event-free survival (EFS), and
disease-free survival (DFS) were 78.2%, 58.1%, and 72.3%
5 years after HSCT. Results were better in transplantations
performed in 2000 or later and in children less than 10 years old
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CD40 ligand (CD40L) deficiency (X-linked hyper-IgM syn-
drome type 1 [OMIM#308230])1,2 is a rare X-linked primary im-
munodeficiency (PID) caused by mutations in CD40LG on
chromosome Xq26.3-Xq27.1, which encodes the transmembrane
CD40L glycoprotein (CD154, OMIM#300386).3-8 Mutations in
CD40LG result in altered costimulatory T-lymphocyte function,9
which impairs B-lymphocyte isotype switching, antibody produc-
tion, and dendritic cell signaling.Myeloid cell function and devel-
opment are also impaired.10,11 This leads to increased
susceptibility to bacterial and intracellular pathogens.
Patients usually present in early childhood with recurrent upper
and lower respiratory tract infections and Pneumocystis jirovecii
pneumonia.12,13 Acute or chronic diarrhea is frequently associ-
ated with Cryptosporidium species infection, which can lead to
severe biliary tract disease, especially sclerosing cholangitis
and cirrhosis and rarely cholangiocarcinoma, hepatocellular car-
cinoma, and adenocarcinoma.14
An increased frequency of central nervous system infections
(enteroviral meningoencephalitis15 and JC virus progressive
multifocal leukoencephalopathy),16 often resulting in neurode-
generation,12,17 has been reported.
Historically, long-term survival with conservative therapy has
been poor, with 20% to 50% of patients surviving to the third
decade.12,18,19 Hepatic disease and severe infections represent the
major causes of death,12 and many patients have chronic comor-
bidities.18 More recent data show a median survival time from
diagnosis of 25 years in 109 patients with X-linked hyper-IgM
syndrome.20
Currently, the only curative treatment is hematopoietic stem
cell transplantation (HSCT). Numerous published case re-
ports21-36 and single-center experiences37-42 report encouraging
results, especially with an HLA-matched sibling donor (MSD).
However, there is a risk of complications, and overall survival
(OS) is not optimal.18 In the European retrospective analysis of
38 patients with CD40L deficiency receiving HSCT,43 OS was
68%, with 32% of patients dying from infection-related compli-
cations, particularly severe cryptosporidiosis. Transplantation
was curative in 58% of patients, 72% of those without hepatic dis-
ease. Pre-existing lung disease was the most important adverse
risk factor.
The choice of performing early HSCT using myeloablative
conditioning (MAC) or a later transplantation with reduced-
intensity conditioning (RIC) or treating patients with full
supportive treatment only is still debated. Guidelines for the
management of these patients were proposed by the European
Society for Blood and Marrow Transplantation (EBMT)/
European Society for Immunodeficiencies (ESID) Inborn Errors
Working Party (IEWP) in 2011.44 Recommendations about
HSCT based on donor type and disease-related complication
status favored HSCT at diagnosis when an MSD was available
and medical support until development of early complications
for matched unrelated donors (MUDs) or mismatched unrelated
donors (MMUDs) and progressive organ damage for mismatched
family donors (MMFDs). A recently published study45 reported
improved survival in 29 Japanese patients undergoing HSCT
(OS, 86.2%), with better event-free survival (EFS) and disease-
free survival (DFS) in children younger than 5 years of age atthe time of transplantation. A multicenter study comparing
outcomes with or without HSCT showed an 85% OS in 67
patients in the transplantation group.20
We report the results of a retrospective international
collaborative study on patients who underwent HSCT for
CD40L deficiency between 1993 and 2015, reported in the
Stem Cell Transplant for Primary Immune Deficiencies in Europe
(SCETIDE) and EBMT registries and from North American
Primary Immune Deficiency Treatment Consortium (PIDTC)
centers. We analyzed the outcome and relevance of different
variables with respect to survival and cure rate after HSCT,
aiming to individualize specific risk factors for patients and
determine the optimal timing and type of HSCT.METHODS
Data collection
Transplantation centers known to have performed HSCT in CD40L-
deficient patients were identified from SCETIDE and EBMT registries (for
European, Saudi Arabian, and Australian centers) and through the network of
PIDTC centers in the United States.
Retrospective data collection on the outcome of HSCTwas performed with
a comprehensive questionnaire for 130 patients with CD40L deficiency
undergoing transplantation in 36 centers in 18 countries over 4 continents (see
Table E1 in this article’s Online Repository at www.jacionline.org) between
1993 and 2015, with a follow-up (FU) between 0.2 and 17.6 years (median,
4.1 years). Data from 35 patients have been previously published.*
Patients in whom the diagnosis of CD40L deficiency was based on
molecular genetic analysis, evidence of absent protein, or both were included
TABLE I. Clinical features of CD40L-deficient patients before the first HSCT
Patients’ features before HSCT Total*
All patients
(n 5 130), median (range)
HSCT up to 1999
(n 5 24), median (range)
HSCT since 2000
(n 5 106), median (range) P value
Age at diagnosis (mo) 126 11.0 (0-131) 13.0 (3-129) 10.7 (0-131) .2466
Age at HSCT (y) 130 4.0 (0.5-38.3) 8.5 (1.0-18.1) 3.4 (0.5-38.3) .0012
Interval between diagnosis and HSCT (y) 126 2.0 (0-27.4) 3.9 (0.9-16.2) 1.5 (0-27.4) .0012
Total* No. Percent No. Percent No. Percent P value
CD40L expression 87 .4525
Absent 71 82 11 92 60 80
Low 16 19 1 8 15 20
Age at HSCT (y) 130 .0320
0-5 79 61 10 42 69 65
5-10 26 20 5 21 21 20
>10 25 19 9 37 16 15
Organ damage before HSCT 119 45 38 15 71 30 31 .0005
Infections before HSCT
All 129 117 91 22 96 95 89 .6919
URTI 124 60 48 14 67 46 45 .0659
LRTI 125 86 69 15 71 71 68 .7756
PJP 108 47 44 7 39 40 44 .6643
Cryptosporidium species 118 29 25 9 47 20 20 .0189
Need of ventilation 106 38 36 6 38 32 36 .8812
Chronic lung disease 114 17 15 5 29 12 12 .1305
Neutropenia 123 57 46 11 52 46 45 .5422
Oral ulcers 122 26 21 6 29 20 20 .3869
Failure to thrive 125 37 30 7 33 30 29 .6812
Protracted diarrhea 126 31 25 10 48 21 20 .0073
Liver disease 126 33 26 11 50 22 21 .0052
Sclerosing cholangitis 125 28 22 9 43 19 18 .0211
Autoimmunity 111 6 5 1 7 5 5 .5636
Malignancies 119 3 3 2 10 1 1 .0800
IG supplementation 125 123 98 19 90 104 100 .0271
Cryptosporidium species prophylaxis 100 31 31 7 54 24 28 .1035
PJP prophylaxis 113 109 97 15 88 94 98 .1068
Organ damage was defined as the presence of chronic lung disease, liver alterations (sclerosing cholangitis or liver fibrosis or hepatitis), or both. Significant P values (P < .05) are
shown in boldface.
IG, Immunoglobulins; LRTI, lower respiratory tract infection; PJP, Pneumocystis jirovecii pneumonia; URTI, upper respiratory tract infection.
*Number of patients with available data.
All liver alterations, including also ascending cholangitis, mild hepatic portal inflammation, and minimal alterations.
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protein expression data but were included based on their clinical history and
presentation. Of these, 3 underwent transplantation before 2000 and died. At
that time, molecular diagnosis was not always performed, and it was not
possible to pursue diagnosis after death.
Centers were responsible for acquiring informed consent from patients and
families for data collection and for quality of data entry.Patients’ characteristics
Patients’ clinical features before HSCT are summarized in Table I by year
of HSCT, showing significant differences between the 2 historical cohorts. In
particular, patients who underwent transplantation before 2000 underwent
transplantation at an older age and at a greater interval after diagnosis, and
they were clinically more compromised (greater organ damage, especially
liver disease, before transplantation).
Median age at diagnosis was 11 months (range, 0-131 months) and was not
significantly influenced by historical period. Forty-seven patients received a
diagnosis in the first 6 months of life, 11 at birth because of a positive family
history. CD40L protein expression on activated CD41 T lymphocytes was
available for 87 (66.9%) patients, absent in the majority (81.6%), and most
frequently quantified by using flow cytometry. Diagnosis was confirmed by
CD40L gene analysis in 108 (83.1%) patients, which showedmainly deletionsand missense mutations (see Table E2 in this article’s Online Repository at
www.jacionline.org). CD40L expression before HSCT did not significantly
differ in patients with these types of mutations.
Additional details on the cohort’s clinical characteristics are reported in the
Methods section in this article’s Online Repository at www.jacionline.org.Transplantation
Patients’ performance status at the time of transplantation was determined
based on the Lansky or Karnofsky score according to age. Most patients
(70.2%) who underwent transplantation after 2000 had a score of 90 or greater
at first HSCT. These data were unavailable for most transplantations
performed before 2000.
Characteristics of first HSCTs, second HSCTs, boosts, and donor
lymphocyte infusions (DLIs) are summarized in Tables II and E3 in this arti-
cle’s Online Repository at www.jacionline.org. Conditioning regimens were
grouped according to their intensity and toxicity features into the following
4 types: MAC, myeloablative conditioning with low toxicity (MAC low
tox), RIC,50,51 and nonmyeloablative (NMA) conditioning (see Fig E1 and
Table E4 in this article’s Online Repository at www.jacionline.org). MAC
was the most commonly used conditioning regimen for first transplantations
in the historical group (92%), whereas after 2000, the use of RIC and MAC
low tox regimens has increased (24% and 20%, respectively; P 5 .0034).
TABLE II. Characteristics of the first HSCT performed on 130 CD40L-deficient patients
First HSCT
characteristics Total*
All patients (n 5 130)
HSCT up to 1999
(n 5 24)
HSCT since 2000
(n 5 106)
P valueNo. Percent No. Percent No. Percent
Conditioning regimen 129 .0034
MAC 79 61 22 92 57 54
MAC low tox 21 16 0 0 21 20
RIC 27 21 2 8 25 24
NMA 2 2 0 0 2 2
GVHD prophylaxis 129 1.0000
Yes 123 95 23 96 100 95
No 6 5 1 4 5 5
Donor type 123 .3092
MSD 37 30 10 45 27 27
MUD 46 37 7 32 39 39
ad. vol. 46 100 7 100 39 100
UCB 0 0 0 0 0 0
MMUD 36 29 5 23 31 31
ad. vol. 29 81 5 100 24 77
UCB 7 19 0 100 7 23
MMFD 4 3 0 0 4 4
Stem cell source 129 .0006
BM 86 67 24 100 62 59
PBSC 33 25 0 0 33 31
UCB 10 8 0 0 10 10
Significant P values (P < .05) are shown in boldface.
ad. vol., Adult volunteer; NMA, nonmyeloablative conditioning.
*Number of patients with available data.
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numbers in this group, this was not included in statistical analyses. Because
no data about busulfan pharmacokinetics (area under the curve) were avail-
able, busulfan-containing regimens were divided between MAC and RIC
groups based on the total dose of busulfan administered in case of combination
with fludarabine (14.3-25.0mg/kg inMAC and 4.0-13.6mg/kg in RIC, see Fig
E1). In the other cases classification as MAC was based on other features (eg,
combination with cyclophosphamide) and not solely on busulfan dose.
Donor type was defined as follows: MSD, MUD (10/10, 12/12, or 8/8 HLA
match), and MMUD (with >_1 mismatch) and MMFD (with >_1 mismatch),
usually a haploidentical parent. Data about methods used for HLA match
testing were available for only 51.3% of the procedures, with molecular
techniques used in the majority of cases (75.3%). Data from donors with
unavailable or inaccurate information about degree of matching (number of
loci studied < 8 for nonsibling donors) were excluded from statistical analysis.
MSDs were the preferred donor types before 2000. The proportion of
unrelated donors has since increased for bothmatched andmismatched donors
(39% and 31%, respectively), mainly represented by adult volunteers
(Table II).
The stem cell source was bone marrow (BM), peripheral blood stem cells
(PBSCs), and umbilical cord blood (UCB). Until 1999, BMwas the only stem
cell source used for first HSCT. Use of PBSCs and UCB became subsequently
more common (31% and 10% HSCT, respectively; P 5 .0006; Table II).
T-lymphocyte depletion of the graft was performed in 28 procedures,
mainly through positive selection of CD341 cells (n5 19). This techniquewas
used in all cases of PBSC transplantations from MMFD (n 5 4) and in 8
MMUD and 7 MUD transplants. In 6 recent unrelated donor PBSC transplan-
tations performed in a single center since 2012, T-cell receptor ab depletion
was used. Ex vivo graft manipulation details are reported (see Table E5 in
this article’s Online Repository at www.jacionline.org). In vivo T-lymphocyte
depletionwas performedmainly by using antithymocyte globulin (51.3%) and
alemtuzumab (20%), especially in the unrelated donor setting (see Table E4
and data not shown).
Graft-versus-host disease (GVHD) prophylaxis was used in most proced-
ures (92%). No additional GVHD prophylaxis was administered in 8 of 19transplantations with CD341 cell selection and in 1 boost. GVHD prophylaxis
regimen was based on cyclosporine administration in 88.4% of cases, either
alone (25.4%) or in combination with other drugs, mainly methotrexate
(29.7%), mycophenolate mofetil (19.6%), or corticosteroids (9.5%). Acute
GVHD was graded according to EBMT guidelines and defined as severe
when grade 3 or greater. Chronic GVHDwas classified as extensive or limited
based on the clinical severity and extent of target organ involvement.
Donor chimerism was defined as complete if 95% or more cells were of
donor origin, partial if between 5% and 95% cells were of donor origin, and
absent if donor cells represented 5% or less of total cells. Partial chimerism
analysis on purified cell subpopulations (granulocytes, CD31 T lymphocytes,
and CD191 B lymphocytes) was analyzed in a subgroup of patients subdi-
vided into predominantly donor (50% to 94%) and predominantly recipient
(6% to 49%) cells. Fluorescence in situ hybridization or molecular testing
based on short-tandem repeats analysis was used to monitor donor cell
chimerism.
Additional details are reported in the Methods section in this article’s On-
line Repository.Statistical analysis
The description of continuous variables was done by using medians and
ranges or interquartile ranges, whereas the comparison between groups was
based on the Wilcoxon rank sum test. Categorical variables were analyzed
through frequency distributions and compared by using the x2 or Fisher exact
test, as appropriate.
OS, EFS, and DFS calculations were performed both in thewhole cohort of
patients and in the subgroups of patients undergoing transplantation before
(historical cohort) or since 2000. Comparisons of these 2 groups are shown in
Figs 1 and 2 and Fig E2 in this article’s Online Repository at www.jacionline.
org. Results from the analyses focused on most patients undergoing recent
transplantation, which are more representative of current clinical practice,
are reported in Table III. EFSwas calculated as the time fromHSCT to the first
of the following events: graft failure/absent engraftment; need for second
HSCT, boost, or DLI; grade 4 acute GVHD or extensive chronic GVHD;
FIG 1. Characteristics influencing OS in patients receiving first HSCT before/after 2000. A, Age at HSCT. Sur-
vival curves of patients less than 5 and 5 to 10 years old at HSCT undergoing transplantation before 2000 are
superimposed. B, Organ damage before HSCT. C, Cryptosporidium species infection before HSCT. D, All
liver alterations. E, Sclerosing cholangitis. F, Waiting time to HSCT from diagnosis. Under each graph,
the number of patients at risk at each FU time point after HSCT is reported for all patient groups. OS curves
of different patient groups are represented by solid or dashed lines. For each of them, a specific label is re-
ported near the corresponding curve.
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FIG 2. Characteristics influencing EFS in patients receiving first HSCT before/after 2000. A, Age at HSCT. B,
Organ damage before HSCT. C, Sclerosing cholangitis before HSCT. D, Donor type. E, Source of stem cells.
F, Conditioning regimen. Under each graph, the number of patients at risk at each FU time point after HSCT
is reported for all patient groups. EFS curves of the different groups are represented by solid or dashed
lines. For each of them, a specific label is reported near the corresponding curve. CB, Cord blood; PB, pe-
ripheral blood.
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TABLE III. OS, EFS, and DFS in CD40L-deficient patients undergoing transplantation since the year 2000
Characteristics
OS EFS DFS
No. of
events/no.
of patients*
2-y FU
(%)
SE
(%)
5-y FU
(%)
SE
(%) P value
No. of
events/no.
of patients*
2-y
FU (%)
SE
(%)
5-y
FU (%)
SE
(%) P value
No. of
events/no.
of patients*
2-y FU
(%)
SE
(%)
5-y FU
(%)
SE
(%) P value
Overall 16/106 86.1 3.5 82.2 4.3 — 37/106 64.2 3.6 61.3 5.1 — 20/106 78.7 4.5 77.1 4.7 —
Age at HSCT (y) .0005 .0238 .0001
<5 6/69 91.0 3.5 91.0 3.5 24/69 64.3 6.1 62.1 6.3 8/65 85.4 4.9 85.4 4.9
5-10 3/21 89.3 7.2 82.4 9.4 4/21 85.2 7.9 78.1 9.3 4/26 85.5 7.9 79.8 9.2
>_10 7/16 58.3 13.8 43.8 16.1 9/16 33.3 13.3 33.3 13.3 8/15 38.1 14.3 38.1 14.3
Age at diagnosis (mo) .2777 .0148 .06
<12 7/59 89.6 4.0 86.8 4.8 15/59 72.8 6.1 72.8 6.1 8/60 87.2 4.6 84.4 5.3
>12 9/45 80.6 6.2 75.8 7.5 22/45 51.0 8.0 44.6 8.2 12/43 64.8 8.5 64.7 8.5
Time between diagnosis
and HSCT (y)
.0014 .1226 .0025
<_2 3/59 94.3 3.2 94.3 3.2 17/59 69.7 6.5 66.8 6.9 4/53 90.5 4.6 90.5 4.6
>2 13/45 74.8 6.6 67.2 7.9 20/45 55.8 7.7 52.8 7.8 16/50 65.5 7.4 62.5 7.7
Organ damage before
HSCT
.0014 .0071 <.0001
No 5/68 92.2 3.4 92.2 3.4 16/68 74.5 5.6 74.5 5.6 4/60 92.9 3.4 92.9 3.4
Yes 10/30 72.4 8.4 62.7 9.8 15/30 49.5 9.6 45.7 9.6 12/28 58.3 9.7 53.9 10.0
Chronic lung disease .2545 .1433 .1026
No 10/85 89.0 3.5 86.9 4.0 24/85 71.0 5.2 69.0 5.4 11/79 85.1 4.5 82.7 5.0
Yes 3/12 73.3 13.2 73.3 13.2 6/12 45.8 15.0 45.8 15.0 4/12 64.8 14.3 64.8 14.3
Cryptosporidium species
infection (gastrointestinal)
.001 .0603 <.0001
No 7/79 90.7 3.4 90.7 3.4 23/79 69.9 5.5 67.9 5.7 7/74 89.7 4.0 89.7 4.0
Yes 7/20 68.8 10.7 60.2 12.3 9/20 50.0 12.1 50.0 12.1 8/18 55.7 13.2 44.6 14.5
Protracted diarrhea .0023 .5314 .0371
No 8/84 90.2 3.3 90.2 3.3 28/84 65.8 5.6 61.9 5.9 10/76 84.4 4.7 84.4 4.7
Yes 8/21 70.2 10.2 56.3 12.2 9/21 56.1 11.0 56.1 11.0 8/22 65.5 10.7 60.1 11.1
Sclerosing cholangitis .0003 .0126 <.0001
No 8/85 90.0 3.4 90.0 3.4 26/85 67.7 5.5 65.7 5.6 8/79 88.3 4.0 88.3 4.0
Yes 8/19 67.5 11.0 52.1 12.9 11/19 43.0 12.0 36.8 11.8 10/18 46.0 12.4 38.3 12.5
Liver disease .002 .0666 .0009
No 8/82 89.7 3.5 89.7 3.5 26/82 66.7 5.6 64.6 5.8 10/80 85.3 4.4 85.3 4.4
Yes 8/22 71.8 9.9 57.6 12.1 11/22 49.7 11.4 44.2 11.4 10/22 53.8 11.6 47.1 12.0
Pneumonias .6865 .7624 .6436
No 6/33 84.2 6.5 76.5 9.4 13/33 65.4 8.5 56.7 9.3 7/32 71.4 9.5 71.4 9.5
Yes 10/71 86.7 4.2 84.4 4.6 23/71 64.6 6.7 64.6 6.7 11/65 82.9 5.0 80.2 5.5
PJP .6862 .9663 .9081
No 6/50 87.2 4.9 87.2 4.9 16/50 68.0 6.9 64.9 7.2 8/51 82.0 6.0 82.0 6.0
Yes 6/40 87.2 5.4 83.1 6.5 13/40 63.6 8.3 63.6 8.3 6/35 83.6 6.9 78.3 8.2
URTI .4377 .1809 .1457
No 7/57 88.3 4.5 84.6 5.7 16/57 66.6 7.1 66.6 7.1 7/55 86.1 5.5 82.0 6.6
Yes 9/46 82.4 5.7 78.5 6.6 20/46 60.0 7.3 54.8 7.6 11/40 70.0 7.7 70.0 7.7
(Continued)
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TABLE III. (Continued)
Characteristics
OS EFS DFS
No. of
events/no.
of patients*
2-y FU
(%)
SE
(%)
5-y FU
(%)
SE
(%) P value
No. of
events/no.
of patients*
2-y
FU (%)
SE
(%)
5-y
FU (%)
SE
(%) P value
No. of
events/no.
of patients*
2-y FU
(%)
SE
(%)
5-y FU
(%)
SE
(%) P value
Need of ventilation before
HSCT
.5732 .8708 .6827
No 7/58 89.2 4.2 86.2 5.0 19/58 65.9 6.7 63.3 6.9 10/55 80.8 5.9 77.4 6.6
Yes 5/32 82.7 7.2 82.7 7.2 10/32 67.3 8.6 67.3 8.6 4/29 84.1 7.4 84.1 7.4
Neutropenia .3152 .3861 .8773
No 10/56 82.6 5.3 79.3 6.0 17/56 67.3 6.7 67.3 6.7 10/55 80.8 6.0 77.1 6.7
Yes 5/46 88.8 4.7 88.4 4.7 18/46 62.1 7.6 55.9 8.0 7/39 79.2 7.2 79.2 7.2
Oral ulcers .3384 .8886 .8351
No 9/81 89.7 3.5 87.6 4.0 26/81 68.1 5.5 64.2 5.8 13/81 82.4 4.8 80.2 5.1
Yes 4/20 83.8 8.6 73.3 12.4 7/20 61.5 11.5 61.5 11.5 2/14 80.2 12.8 80.2 12.8
FTT .868 .74 .4987
No 11/74 87.4 3.9 81.7 5.5 25/74 63.3 5.9 63.3 5.9 11/69 84.1 4.7 81.6 5.2
Yes 5/30 81.8 7.4 81.8 7.4 12/30 63.4 9.5 51.9 10.7 6/27 70.6 10.6 70.6 10.6
No Cryptosporidium species
prophylaxis before HSCT
.8896 .9309 .9141
No 6/63 84.8 4.7 84.8 4.7 21/63 65.7 6.4 63.1 6.6 10/62 80.9 5.6 80.9 5.6
Yes 3/24 87.5 6.8 87.5 6.8 8/24 61.9 10.9 61.9 10.9 3/21 85.7 7.6 85.7 7.6
Conditioning regimen .0073 <.0001 .0031
MAC 5/57 92.7 3.5 90.0 4.3 10/57 81.6 5.3 81.6 5.3 6/58 91.0 3.9 88.3 4.6
RIC 8/25 71.8 9.1 62.8 11.5 16/25 41.9 10.2 32.6 9.8 9/23 55.0 11.6 55.0 11.6
MAC low tox 1/21 93.3 6.4 93.3 6.4 8/21 42.8 15.8 42.8 15.8 1/17 83.3 15.2 83.3 15.2
NMA 1/2 50.0 35.4 k k 2/2 0 § k k 2/3 33.3 27.2 33.3 27.2
Donor type .0373 .0605 .2619
MSD 3/27 88.8 6.1 88.8 6.1 5/27 85.0 6.9 80.8 7.8 4/27 88.8 6.1 84.6 7.1
MUD 2/39 94.0 4.1 94.0 4.1 13/39 61.6 9.0 56.9 9.5 5/38 94.2 4.0 77.6 9.3
MMUD ad. vol. 7/24 72.7 9.8 58.1 15.2 10/24 52.1 11.9 52.1 11.9 7/24 72.6 9.8 63.6 12.0
MMFD 1 mmUCB 3/11 81.8 11.6 70.1 14.7 6/11 45.5 15.0 45.5 15.0 2/11 90.9 8.7 77.9 14.1
Stem cell source .0936 .0035 .1123
BM 6/62 91.7 3.6 88.3 4.8 15/62 75.5 5.8 73.0 6.1 8/60 84.1 5.3 84.1 5.3
PBSC 7/33 78.4 8.0 72.8 9.2 17/33 43.6 10.1 37.4 10.4 10/36 65.2 10.0 58.7 10.9
UCB 3/10 70.0 14.5 70.0 14.5 5/10 50.0 15.8 50.0 15.8 2/8 75.0 15.3 75.0 15.3
Organ damage was defined as the presence of chronic lung disease, liver alterations (sclerosing cholangitis or liver fibrosis or hepatitis), or both. EFS and OS were calculated from the first HSCT, whereas DFS was calculated from the last
procedure (ie, second HSCT, boost, or DLI), and thus the analyses were performed considering the covariates at the proper procedure. Significant P values (P < .05) are shown in boldface.
ad. vol., Adult volunteer; FTT, failure to thrive; mm, mismatched; PJP, Pneumocystis jirovecii pneumonia; URTI, upper respiratory tract infection.
*Number of patients with available data.
All liver alterations, including ascending cholangitis, mild hepatic portal inflammation, and minimal alterations.
The NMA group is reported for descriptive purposes only but has not been included in the statistical analyses (log-rank test) because of its low numbers.
§SEs were not estimable at this time point.
kNo subjects at risk at this time point.
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HSCT; or death. Events for calculation of DFS were the ongoing requirement
of immunoglobulin supplementation 2 years after the last procedure and death,
whereas the only event considered for OS was death from any cause. Patients
observations were censored at the date of last contact when no events were
observed. The Kaplan-Meier method was used to estimate the probabilities
of OS, EFS, and DFS, with SEs calculated according to the methods of Green-
wood. Curves were compared by using the log-rank test, and pairwise compar-
isons were adjusted for multiplicity according to themethod of Sidek, whereas
the Cox proportional hazard model was used for multivariable analyses. All
tests were performed 2-sided, with a .05 level of significance.
Analyses were performed in SAS 9.3 (SAS Institute, Cary, NC) and R 3.2.2
(R Foundation for Statistical Computing, Vienna, Austria) software.RESULTS
Overall survival
Data from 154 procedures were collected: 130 first, 13 second,
and 1 third HSCT; 6 cell boosts (infusions of cells from the same
donor without conditioning); and 4 DLIs. Most were performed
since 2000. Median age at first transplantation was 4.0 years
(range, 0.5-38.3 years). Patients from the historical cohort
underwent transplantation at an older age (median, 8.5 years)
compared with those treated after 2000 (median, 3.4 years;
P 5 .0012). Median time interval between diagnosis and HSCT
was 2.0 years, although it was slightly higher for HSCT before
2000 (3.9 years, P 5 .0012, Table I).
OS after first HSCT improved,43 reaching 81% and 78.2% at 2
and 5 years, respectively. In particular, as observed in patients
with other PIDs, outcome improved after 2000, likely because
of improvement in transplant-related procedures and patient man-
agement (5-year OS before 2000, 58.3%; OS since 2000, 82.2%;
P 5 .0030).
Patients undergoing transplantation at less than 5 years of age
reached nearly 90% OS at 2 and 5 years after HSCT. Those older
than 10 years at treatment had a 37.8% OS at 5 years (P <.0001).
This ‘‘age effect’’ was also observed in patients undergoing trans-
plantation since 2000, although a slight improvement in OS was
noted in older patients (OS of 43.8% at 5 years, Fig 1, A, and
Table III). Age at diagnosis (<12 vs >12months) did not influence
OS. Waiting time between diagnosis and HSCT had an effect on
outcome, with significantly better survival for those undergoing
transplantation within 2 years from diagnosis (Fig 1, F).
Pre-existing organ damage (mainly chronic lung disease, liver
dysfunction, or both) before HSCT negatively influenced
outcome (OS of 61.5% at 2 years and 55.6% at 5 years; without
organ damage: OS of 92.9% at 2 and 5 years; P < .0001). Liver
disease, especially sclerosing cholangitis, was the most important
adverse risk factor (OS of 51.2% and 46.9% at 5 years, respec-
tively; P < .0001), followed by protracted diarrhea (OS of
55.5% at 5 years, P 5 .0002) and gastrointestinal infection by
Cryptosporidium species (OS of 59.6% at 5 years, P 5 .0004).
These clinical features were confirmed to negatively influence
outcome also in patients undergoing most recent transplantations,
even if less profoundly (Fig 1,B-E, and Table III). The presence of
chronic lung disease, previously a significant risk factor,43 did not
significantly influence survival in recent transplantations. Type of
CD40L gene mutation, previous clinical history of respiratory
tract infections, including Pneumocystis jirovecii pneumonia,
requirement of ventilation before transplantation, neutropenia,
oral ulcers, failure to thrive, and absent Cryptosporidium species
prophylaxis before HSCT had no significant influence on OS.Use of myeloablative conditioning regimens resulted in better
survival as compared with RIC after the year 2000 (P 5 .0073),
with significant differences emerging at pairwise comparison be-
tween MAC low tox or MAC and RIC (P5 .0197 and P5 .0258,
respectively; see Table E6 in this article’s Online Repository at
www.jacionline.org). Of note, OS in patients receiving MAC
improved in recent years (Table III and see Fig E3, A, in this
article’s Online Repository at www.jacionline.org).
Finally, a significant difference in OS emerged between
different donor types (whole cohort, P 5 .0198; >2000,
P 5 .0373), with better survival achieved with matched donors
(both sibling and unrelated donors). However, at pairwise com-
parison, the difference in OS between MUDs and MMUDs was
attenuated in most recent years (P 5 .0545), reflecting an
improved outcome also in the MMUD setting. Moreover, among
adult volunteer donors, there seemed to be a negative trend in
OS, with increasing number of mismatches (Table III and see
Fig E3, B, and Table E7 in this article’s Online Repository at
www.jacionline.org).EFS
EFS after first HSCT was 62.6% and 58.1% at 2 and 5 years,
respectively, with only a slight improvement after the year 2000
(Table III). It was very low (25.2%) in patients undergoing trans-
plantation at 10 years of age or older, but an improvement was
observed in recent years in this subgroup (Fig 2, A). Age at diag-
nosis significantly influenced EFS, which appeared better in those
receiving early diagnosis (<1 year of age), whereas the time inter-
val from diagnosis to HSCTwas not relevant (Table III and data
not shown).
Pre-existing organ damage significantly affected EFS, in
particular the presence of sclerosing cholangitis, both in historical
and recent transplantations, in spite of an improvement in the
latter (Fig 2, B andC, and Table III). Other clinical features before
HSCT and genotype did not strongly influence EFS.
MAC was associated with greater EFS (81.6% at 5 years in
patients undergoing transplantation since 2000, P < .0001; Fig 2,
F, and Table III) as compared with MAC low tox and RIC (see
Table E6), possibly explained by better engraftment of donor cells
with this regimen or use in less compromised patients. Stem cell
source resulted in significant differences, with best EFS associ-
ated with BM (73% at 5 years’ FU in patients undergoing trans-
plantation since 2000; Fig 2, E, and Table III).
In recent years, no significant differences in EFS emerged
between donor types in univariate analysis (Fig 2, D, and Table
III). However, multivariable EFS analysis, which was performed
on patients undergoing transplantation after 2000 with complete
data (n 5 96), showed donor type and conditioning regimen to
be the most significant influences. In particular, patients receiving
HSCT from mismatched or MUD donors showed a 4.2- and 3.3-
fold increase, respectively, in the hazard of event compared with
those from MSDs (P5 .0189 and P5 .0607). RIC use was asso-
ciated with a 3.2-fold increased hazard ratio, as compared with
MAC (P 5 .0323). The presence of pre-existing organ damage
before HSCT was associated with a 2.7-fold increased hazard
(P 5 .1036). Pretransplantation sclerosing cholangitis and age
at HSCT had no relevant role on EFS (see Table E8 in this article’s
Online Repository at www.jacionline.org).
Results of DFS analysis are described in the Results section and
Fig E2 in this article’s Online Repository at www.jacionline.org.
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Twenty-six deaths were reported, most of them transplant-
related (n 5 22 [84.6%]). Most occurred within 6 months of
HSCT (n5 20 [76.9%]), mainly caused by infections (see Fig E4
in this article’s Online Repository at www.jacionline.org). Liver
failure was the cause of death of 2 patients with pre-existing scle-
rosing cholangitis who experienced severe liver GVHD, Crypto-
sporidium species infection, and veno-occlusive disease after
transplantation. Graft rejection was reported as the primary cause
of death in 3 patients.
Four non–transplantation-related deaths were caused by pro-
gression of original disease. In 2 cases neurologic complications
occurred, with progressive neurodegeneration in 1 patient and
worsening progressive multifocal leukoencephalopathy in
another patient with a history of JC virus encephalitis before
transplantation. In the other 2 cases infection (n 5 1) and
deteriorating liver function (n5 1) were complicated by previous
graft rejection (Table IV).Rejection
Eighteen patients (14.8% of 122 patients with available data)
experienced graft rejection after first transplantation (Table IV).
Most occurred within 6 months of HSCT (72.2%), mainly after
unrelated donor transplantation (83.3%, 10 MUDs and 5
MMUDs, of which 3 were adult volunteers and 2 were UCB).
The stem cell source was BM, PBSCs, or UBC in 8, 8, and 2 pa-
tients, respectively. Positive selection of CD341 cells was per-
formed in 3 procedures. RIC was the most common
conditioning regimen (n 5 8), followed by MAC (n 5 5), MAC
low tox (n5 3), and NMA (n5 2). Most patients experienced in-
fections in the first 6 months of FU after first transplantation,
mainly of viral origin. No signs of acute GVHD were observed
in 72.2% of patients in this subgroup.
Most patients who rejected their first HSCT received further
therapeutic interventions (10 second HSCT, 1 third HSCT, and
1 cell boost) after a median of 11.7 months from the first
transplantation. Most were alive at the last FU (81.8%), and in
66.7% immunoglobulin supplementation could be discontinued.
Seven patients did not receive additional cell therapy procedures.
Three of these patients continued supportive care with immuno-
globulin supplementation and are alive, whereas the remaining 4
died. Deaths occurred at a median of 25 months after HSCT,
mainly because of disease progression (infections and deterio-
rating liver function). Donor type, stem cell source, and
occurrence of viral infections early after HSCT or acute GVHD
did not significantly influence the risk of rejection.
Information on additional procedures can be found in the
Results section and Table E3 in this article’s Online Repository at
www.jacionline.org.Engraftment and cure rate
Transplantation resulted in complete or partial donor chime-
rism in most patients that was stable over time to the last FU (Fig
3,A). Data about lineage-specific donor chimerismwere available
only for a subgroup of patients. Median lineage-specific donor
chimerism remained stable at 88% or greater up to the last FU
(>1 year after last procedure) in both granulocytes and T lympho-
cytes, whereas in B lymphocytes a slight reduction in donor
chimerism was observed over time (median donor chimerism,75%; Fig 3,B). At the last available FU (>1 year) after the last pro-
cedure (see Fig E5 in this article’s Online Repository at www.
jacionline.org), donor cell engraftment in granulocytes (CD151
cells) and T lymphocytes (CD31 cells) was complete or predom-
inantly donor in 78.1% and 82.9% patients with available data,
respectively, whereas in B lymphocytes a greater percentage of
predominantly recipient chimerism was observed (35.7%
patients).
Decreasing lineage-specific chimerismwas observed over time
in 27.8% of transplantations (with FU >_1 year among those with
available data). However, in another 25% of transplantations,
increasing donor cell chimerism in T- and B-lymphocyte sub-
populations was observed (Fig 4, A). In this subgroup 3 patients
received DLI infusion with a favorable effect on donor cell
chimerism.
Among survivors who ceased immunoglobulin replacement at
2 or more years after the last procedure and for whom data were
available, T-lymphocyte chimerism was complete or predomi-
nantly donor in 85.2%. B-cell chimerism was full donor in 7 and
predominantly recipient (range, 18% to 43% donor chimerism) in
5 of them (Fig 4, B).
A greater percentage of complete donor chimerism (63.2%)
was observed in transplantations in which patients did not
experience viral infections after HSCT (Fig 4,C). Moreover, viral
infections after HSCT might have influenced T-lymphocyte
chimerism kinetics: in the majority of transplantations in which
decreasing T-lymphocyte chimerism was observed (91.7%), viral
infections occurred in early FU, likely favoring expansion of
autologous lymphocytes to replenish the niche (Fig 4, D, and
data not shown).
Immune reconstitution and data regarding complications (see
Table E9 in this article’s Online Repository at www.jacionline.
org) can be found in the Results section in this article’s Online
Repository.DISCUSSION
This is the largest HSCT series for CD40L deficiency collected
worldwide to date. It includes data from 130 patients undergoing
transplantation over more than 20 years. Interestingly, compar-
ison of the 2 historical cohorts of patients treated before and after
2000 clearly shows how patients’ features have changed over
time, mainly thanks to improvement in diagnostic tools and
clinical management. Most recent patients have undergone
transplantation at a younger age, with a shorter time interval
after diagnosis and lower organ damage burden. All these factors
have contributed to the general HSCT outcome improvement
observed in the past years.
These differences, although interesting, represented a difficulty
in data analysis that was hampered by the presence of potential
confounding between variables. For this reason, for main
outcome measures, we analyzed historical periods separately. In
particular, we decided to perform multivariate analysis only on
the most recent transplantation cohort because it could not be
performed with inclusion of the ‘‘period effect’’ because of
statistical model limitations. Moreover, although the heterogene-
ity induced by the period is relevant, we think that evaluation of
the more recent patient cohort is more interesting because it
reflects more closely the current clinical practice.
Other limitations of the study are represented by the sample
heterogeneity typical of retrospective observational studies,
TABLE IV. Transplant features, therapeutic intervention, and outcome in 18 patients who experienced graft rejection after the first
HSCT for CD40L deficiency
Patient
no.
Year of
first
HSCT
First HSCT stem
cell source
First
HSCT
donor
type
First HSCT
conditioning
regimen
Timing of
rejection/
decreasing
chimerism
Therapeutic
intervention (mo
after first HSCT)
Infections
in early FU*
Acute
GVHD
(grade)
Outcome
(at last FU)
8 2012 BM MUD RIC (Flu/Mel/ATG) 6 mo FU Second HSCT
(28.4)
ADV, EBV
Bacterial sepsis
Yes
(grade I)
Alive (on IVIG)
9 2012 PBSC
(TCRab
depleted)
MUD MAC low tox
(Treo/Flu/ATG)
6 mo FU Second
HSCT (8)
ARVI Yes
(grade II)
Alive (off Ig)
15 2007 BM MSD RIC (Flu/Mel/
alemtuzumab)
>12 mo
FU (6 y)
None ADV,
Cryptosporidium
species
No Alive (on IVIG)
33 2009 PBSC MUD NMA (Flu/ATG) 12 mo FU Second
HSCT (15.4)§
HHV6,
Cryptosporidium
species
No Alive (on IVIG)
37 1996 BM (positive
selection of
CD341 cells)
MUD MAC (Bu/Cy/
aLFA1-2)
6 mo FU None No No Alive (on IVIG)
41 2001 PBSC (positive
selection of
CD341 cells)
MMFD
(haplo)
MAC (Bu/Cy/ATG) 6 mo FU None Whipworm No Deceased
49a 2001 BM (positive
selection of
CD341 cells)
MUD MAC (Bu/Cy/ATG) 6 mo FU Second
HSCT (12.5)
HHV6, ADV
CVL infection
No Alive (off Ig)
74 2014 BM MUD MAC low tox
(Treo/Flu/
Alemtuzumab)
19 mo FU Second
HSCT (21.4)
CMV, parainfluenza
URTI
No Alive (on IVIG)
77 2004 PBSC MMUD MAC low tox
(Treo/Flu/ATG)
6 mo FU Second
HSCT (10.9)
Third
HSCT (31.1)
CMV reactivation
Clostridium difficile
No Alive (off Ig)
83 2001 BM MMUD RIC (Flu/Mel/ATG) 12 mo FU None EBV,
Cryptosporidium
species
BK virus
Yes
(grade I)
Deceased
85 2003 BM MSD RIC (Flu/Mel/
alemtuzumab)
6 mo FU Second
HSCT (21.1)
No No Alive (off Ig)
86 2006 PBSC MUD NMA (Flu/Cy/
alemtuzumab 1
anti-CD45)
6 mo FU None Mycobacteria (gut) No Deceased
89 2011 PBSC MUD RIC (Flu/Mel/
alemtuzumab)
>12 mo
FU (3 y)
None ADV No Alive (on SCIG)
98 2007 UCB MMUD MAC (Bu/Cy/ATG) <1 mo FU Second
HSCT (1.3)
CMV No Alive (off Ig)
102 1997 BM (T-cell
depleted)
MUD MAC (Bu-Cy-ATG 1
in vivo LFA1 CD2)
<1 mo FU Cell boost (1.1) Aspergillus species,
Gram - sepsis
No Deceased
107 2011 PBSC MUD RIC (Flu/Mel/
alemtuzumab)
<3 mo FU Second
HSCT (3.3)
NA NA Alive (off Ig)
124 2014 PBSC (CD45RA
depleted)
MMUD RIC (Bu/Flu/TT/ATG) <3 mo FU None ADV, rhinovirus
Cryptosporidium
species
No Deceased
125 2003 UCB MMUD RIC (Bu/Flu/ATG) <2 mo FU Second
HSCT (2)
NA NA Deceased
ADV, Adenovirus; aLFA, anti-lymphocyte function-associated antigen; ATG, antithymocyte globulin; ARVI, acute respiratory viral infection; Bu, busulfan; CMV, cytomegalovirus;
CVL, central venous line; Cy, cyclophosphamide; Flu, fludarabine; Gram -, Gram-negative; HHV6, human herpes virus 6; Ig, immunoglobulins; IVIG, intravenous
immunoglobulins; Mel, Melphalan; NA, not available; RSV, respiratory syncytial virus; SCIG, subcutaneous immunoglobulins; TCR, T-cell receptor; Treo, treosulfan; URTI, upper
respiratory tract infection.
*First 6 months after first HSCT.
Numbers of HLA loci studied were not specified.
Chimerism decreasing since 6 months of FU.
§This patient also received 2 liver transplantations, 1 before the first HSCT and 1 after the second HSCT. He also experienced chronic GVHD after the second HSCT.
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frames, and by unavoidable intrinsic correlations between
variables, such as the choice of conditioning regimen and the
patient’s clinical status. Furthermore, despite the fact that the
total number of patients included in the study is the highest evercollected for this disease, analyses on patient subgroups were
limited by small sample size, especially when evaluating
different conditioning regimens, donor types, and lineage-
specific donor cell chimerism. This makes it difficult to draw
strong conclusions, especially at the longest FU, but our study
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FIG 4. Engraftment kinetics and T-cell chimerism.A,Donor cell engraftment kinetics represented by the per-
centage of transplantation procedures in which increasing, decreasing, or stable donor cell engraftment
was observed over time 1 or more years after the last procedure. 8One or 8883 patients received DLIs. Data
on unsorted cells, sorted myeloid cells (CD151), B lymphocytes (CD191), and T lymphocytes (CD31) are re-
ported. B, T- and B-cell chimerism at last FU in survivors off immunoglobulin replacement (IG) at 2 or more
years after the last procedure (*). C, T-cell chimerism at last FU, according to the occurrence of viral infec-
tions after HSCT (yes/no).D,Donor T-cell chimerism kinetics over time (increasing/declining/stable), accord-
ing to the occurrence of viral infections after HSCT (yes/no). 888Three patients received DLIs. **Percentage of
transplantations (or subjects) with available data.
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be further explored in the future.
In spite of these difficulties, a number of important new
observations emerge from this report. First, OS after trans-
plantation is now 80%, although there remain significant
differences between those undergoing transplantation at less
than 10 years of age and those undergoing transplantation when
older, even in more recent years. Linked with this was a superior
survival in those undergoing transplantation within 2 years of the
diagnosis of CD40L deficiency and in those without organ
damage, specifically liver disease. Importantly, in recent years,
transplants fromMSDs andMUDs reached similarly good results
in terms of OS but not EFS, which remained lower with unrelated
or mismatched donors. Most patients who received MAC showed
complete engraftment at last FU, whereas RIC was associated
with absent engraftment. New conditioning regimens, specificallyFIG 3. Donor cell engraftment after first HSCT and after the last procedure. A, Overall donor cell engraft-
ment over time represented by percentages of subjects with complete, partial, or absent engraftment on un-
sorted cells at different time points after the first HSCT (left panel) and after the last procedure (right panel).
*Three patients with full chimerism received DLIs. **Percentage of those with available data. B, Median
lineage-specific donor cell engraftment over time at different time points after the first HSCT (left panels)
and after the last procedure (right panels). Data on unsorted cells, sorted myeloid cells (CD15), T lympho-
cytes (CD3), and B lymphocytes (CD19) are reported. For each median value, interquartile range is plotted,
and the number of subjects for whom data were available at each FU is reported in parentheses.=MAC low tox, had superior OS and DFS, but not EFS, as
compared with RIC. This could likely be explained by the
tendency to reach a lower level of myeloid chimerism over time
in patients who received these conditioning regimens, which
might reflect decreased stem cell engraftment.
DFS was more likely with the use of myeloablation. Patients
who ceased immunoglobulins were stable over time, even if
additional procedures (repeat HSCT, boost infusions) were
required to attain this in some cases. Among those with FU of
2 years or greater, median CD40L expression on activated CD41
T cells was 49% in those who stopped immunoglobulin supple-
mentation and 14.5% in those who still needed it. T-lymphocyte
chimerism was complete or predominantly donor in most cured
patients, but unfortunately, a minimum T-cell donor percentage
reliably associated with immunoglobulin independence could
not be retrieved based on available data.
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complications, including graft rejection, although a few were
due to progression of pre-existing neurologic disease. The
rejection rate was 15%, usually occurring early after trans-
plantation, although retransplantation was usually successful.
Among those who rejected their first transplant, only 11.1%
received HSCT fromMSDs, which was in line with the finding of
lower EFS in transplants from other donor types.
A higher percentage of complete donor chimerism (63.2%)was
observed in transplantations in which patients did not experience
viral infection after HSCT. Moreover, viral infection after HSCT
might have influenced T-lymphocyte chimerism kinetics: in the
majority of transplants in which decreasing T-lymphocyte
chimerism was observed (91.7%), viral infections occurred in
early FU, likely favoring the expansion of autologous T
lymphocytes to replenish the niche.
Although we did not compare our results with those in patients
not undergoing transplantation, previous reports have demonstrated
similar survival as ours, although with improved quality of life in
those undergoing HSCT.20 However, from our data, clear trends
emerge. HSCT is curative, but best results continue to be seen in
younger patients, who have the least organ damage and are infec-
tion free. Furthermore, MAC is associated with a better immuno-
logical outcome than RIC regimens, again favoring earlier HSCT.
There is a need for prospective studies directly comparing risks
of HSCT with those of lifelong immunoglobulins and prophy-
laxis. Additionally, advances in gene therapy, and particularly
gene editing, might be attractive as a potential therapeutic
alternative for those for whom HSCT is too risky because of
associated clinical features and poor donor options, particularly
given that infusion of gene-corrected T lymphocytes might be
curative.52
We thank data managers of the different centers for their support in data
collection. We are grateful to all medical and nurse personnel of the
participating clinical and transplant centers for patients’ care. We are indebted
to all the patients and their families for their participation in the study and trust.
Key messages
d HSCT can be curative in patients with CD40L deficiency,
with the best outcome if performed before 10 years of age
and without organ damage, especially sclerosing
cholangitis.
d Superior OS was achieved with matched donors. HSCT
early after diagnosis and use of myeloablative regimens
resulted in greater OS and DFS. EFS resulted improved
with MSDs, MAC, and BM as stem cell source.
d Reduced intensity and nonmyeloablative conditioning
were associated with poor donor cell engraftment.REFERENCES
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